drugset / Trial / NCT03517566
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
Timeline
- Start
- 2018-11-14
- Primary completion
- 2020-07-15
- Completion
- 2020-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADRIFORANT | Small molecule | 3 mg | Oral |
| Subject | ADRIFORANT | Small molecule | 10 mg | Oral |
| Subject | ADRIFORANT | Small molecule | 30 mg | Oral |
| Subject | ADRIFORANT | Small molecule | 50 mg | Oral |